# NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

> **NCT05131763** · PHASE1 · UNKNOWN · sponsor: **Fudan University** · enrollment: 3 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Glioblastoma
- Medulloblastoma
- Colon Cancer

## Interventions

- **BIOLOGICAL:** NKG2D-based CAR T-cells

## Key facts

- **NCT ID:** NCT05131763
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 3 (ESTIMATED)
- **Last updated:** 2021-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05131763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05131763, "NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05131763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*